Dr Reddy’s Laboratories has launched Treprostinil Injection in the U.S. market.
The launched product is a therapeutic equivalent generic version of Remodulin (treprostinil) Injection, approved by the U. S. Food and Drug Administration (USFDA), the Hyderabad-based company said in a release.
Treprostinil injection is a prostacyclin mimetic indicated for patients who require a transition from epoprostenol, to reduce the rate of clinical deterioration.
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.